Dr. Oza-Bedi conducts research on the clinical management of Barrett's esophagus and esophageal adenocarcinoma.
Dr. Chen's research focuses on clinical management of non-malignant conditions of the esophagus, including patients with GERD symptoms not responding to medical therapy, eosinophilic esophagitis, and motility disorders such as achalasia.
Dr. Kurlander is interested in using research methods to improve the effectiveness of health care delivery across an array of common GI conditions, including prevention of gastrointestinal bleeding in patients through the use of acid-reducing medications.
Dr. Kwon's research focuses on diagnostic methods of identifying esophageal dysplasia and cancer, as well as, outcomes of endoscopic therapy (resection and ablation) for these conditions.
Dr. Prabhu's research has evaluated risk factors for esophageal squamous cell carcinoma, and management of Barrett's esophagus with dysplasia or early adenocarcinoma.
The primary focus of Dr. Rubenstein's research is to develop efficient management strategies for identifying Barrett's esophagus and preventing death from esophageal cancer. He also has conducted research on clinical aspects of managing other esophageal disorders, including GERD, eosinophilic esophagitis, and motility disorders such as achalasia. Dr. Rubenstein's research has been funded by the National Institutes of Health, the Department of Veterans Affairs, the Damon Runyon Cancer Research Foundation, and other sources.
Dr. Wang leads one of three Research Centers of the National Cancer Institute's Barrett's Esophagus Translational Research Network (BETRNet) (https://sites.google.com/a/umich.edu/betrnet-project/). BETRNet encompasses a network of Research Centers that are focused on discovering the biological pathways that trigger the development of Barrett's esophagus and esophageal adenocarcinoma using state-of-the-art experimental models and human specimens for translation into early cancer detection, risk stratification and prevention strategies. Through collective leveraging of novel animal and cellular models, genomics, proteomics and imaging as well as access to biospecimens, BETRNet is employing the concept of true team-based science to answer some of the "big" and most puzzling questions in esophageal cancer research.